目的 系統(tǒng)評價生血寧片輔助治療妊娠期貧血的臨床療效和安全性。方法 檢索中國學術期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、維普中文期刊全文數(shù)據(jù)庫（VIP）、萬方數(shù)據(jù)庫、PubMed、Embase、Cochrane Library等數(shù)據(jù)庫，時間為建庫至2020年7月30日，篩選生血寧片輔助治療妊娠期貧血的隨機對照試驗（RCTs）。采用RevMan 5.3軟件對納入的研究進行Meta分析，采用Cochrane系統(tǒng)工具評價文獻質(zhì)量。結果 共納入10篇RCTs，1 208例患者。Meta分析結果示，生血寧片輔助治療妊娠期貧血可以提高治療總有效率[RR=1.20，95% CI=（1.14，1.26）]；紅細胞水平[SMD=2.08，95% CI=（1.51，2.60）]、血紅蛋白水平[SMD=1.91，95% CI=（1.51，2.31）]、轉(zhuǎn)鐵蛋白水平[SMD=2.12，95% CI=（1.95，2.29）]、血清鐵水平[SMD=2.67，95% CI=（1.88，3.45）]均有一定的升高作用，同時可以減少不良反應的發(fā)生[RR=0.17，95% CI=（0.08，0.38）]，所有結果與對照組比較均有統(tǒng)計學意義（P<0.05）。結論 生血寧片輔助治療妊娠期貧血可有效提高患者的總有效率，改善患者癥狀，提高患者紅細胞、血紅蛋白、轉(zhuǎn)鐵蛋白水平及血清鐵水平，降低不良反應發(fā)生率。但納入文獻質(zhì)量較低，存在一定發(fā)表偏倚，仍需要更多大樣本、高質(zhì)量的臨床試驗加以驗證。

Objective To evaluate the clinical efficacy and safety of Shengxuening Tablet in adjuvant treatment of gestational anemia. Methods Data was retrieved from CNKI, VIP, Wanfang, CBM, PubMed, Embase, Cochrane Library and other databases until the 30th July 2020. Screening a randomized controlled trial (RCT) of Shengxuening Tablet in the adjuvant treatment of anemia in pregnancy. Meta-analysis was conducted on the included studies using RevMan 5.3 software, and Cochrane systematic evaluation tool was used to evaluate literature publication bias. Results A total of 10 RCTs and 1 208 patients were included. Meta-analysis results showed that Shengxuening Tablet adjuvant treatment gestational anemia could improve the total effective rate[RR=1.20, 95%CI=(1.14, 1.26)]. It has a certain effect on the increase of red blood cell level[SMD=2.08, 95%CI=(1.51, 2.60)], hemoglobin level[SMD=1.91, 95%CI=(1.51, 2.31)], transferrin level[SMD=2.12, 95%CI=(1.95, 2.29)] and serum iron level[SMD=2.67, 95%CI=(1.88, 3.45)], and can reduce the incidence of adverse reactions in patients[RR=0.17, 95%CI=(0.08, 0.38)], all results were statistically significant (P<0.05). Conclusion Shengxuening Tablet in adjuvant treatment of pregnancy anemia can effectively improve the total effective rate and improve the symptoms of patients; increase the level of red blood cell, hemoglobin, transferrin and serum iron, and reduce the incidence of adverse reactions. However, the quality of the included literature is low, and there is a certain publication bias, which still needs to be verified by more large samples and high-quality experimental data.

R287.4

國家自然科學基金面上項目（81774133）；陜西省教育廳科研課題資助項目（20JK0604）；陜西省中醫(yī)藥管理局科研課題資助項目（LCMSO15）；陜西省自然科學資助項目（806215973013）；咸陽市科學技術資助項目（2017k02-88、2017k02-87）